FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.
PI Update for Pradaxa® (dabigatran etexilate) | BI US PI Update for Pradaxa® (dabigatran etexilate) | BI US Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
Employees join #stayhomeandfoster movement Employees join #stayhomeandfoster movement Employees join #stayhomeandfoster movement
OFEV® (nintedanib) Now Available in the United States OFEV® (nintedanib) Now Available in the United States OFEV® (nintedanib) Now Available in the United States
Results from Phase II MASH trial announced at EASL 2024 Results from Phase II MASH trial announced at EASL 2024 Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024
FDA Approves OFEV® (nintedanib) to Treat IPF | BI US FDA Approves OFEV® (nintedanib) to Treat IPF | BI US Read more about the FDA approval of Boehringer Ingelheim's OFEV, the first Kinase Inhibitor used to treat idiopathic pulmonary fibrosis (IPF).